Innvolution Healthcare expands cath lab business into Indonesia

In August 2026, Indian medical device company Innvolution Healthcare expanded its cardiology business in Indonesia in the next phase of its international growth strategy. The Bangalore-based company, which develops interventional cardiology technologies and cardiac catheterization laboratory (cath lab) systems, appointed international business development consultancy Intralink to identify and recruit a distribution partner to support the launch of its cath lab platform in Indonesia. Founded in 2010, Innvolution has established a strong presence in India and has also already expanded internationally into markets including Nepal, Bangladesh, Central Asia and Africa.

Indonesia represents an important growth opportunity for Innvolution, with demand for cardiovascular care increasing and hospitals continuing to invest in specialist medical technology. The company has already engaged with leading cardiologists in the country and is now seeking a distribution partner with strong cardiology expertise and established relationships with major Indonesian hospitals.

The company has supplied cardiovascular consumables in Indonesia for more than a decade and is now preparing to introduce its cath lab systems to the market, thus offering hospitals access to advanced cardiac imaging technology as a cost-effective alternative to established international brands.

Intralink is an international business development consultancy that is specializing in helping companies secure customers, partners and investors in overseas markets. It operates from 27 locations worldwide including Silicon Valley, Boston, London, Paris, Dusseldorf, Poznan, Tokyo, Shanghai, Taipei, Bangkok, Jakarta and New Delhi.

Impact on the Healthcare Market

Innvolution’s growth mirrors the evolution of India’s healthcare landscape. Responding to rapid advancements in cardiovascular technology and increasing emphasis on preventive care, the company has continually adapted to emerging clinical and market needs.

The combined portfolio of cardiac care products encompasses drug-eluting stents, balloon catheters, and the Cath Lab Pinnacle and Premier, both award-winning and the fastest-growing products in their class. With three manufacturing facilities located in Bengaluru, Vizag, and Jaipur, Innvolution is currently establishing two new Cath Lab manufacturing facilities in Bengaluru and Vizag. The company has already established a broad presence in India and intends to expand into new markets in South-East Asia, Europe, and Africa. Innvolution's wide-ranging cardiovascular care product offerings aim to position the company among the top 1% of Indian medical device manufacturers by 2025, to surpass $100 million in revenue.

Impact on the Next-Gen Cardiovascular Treatments Market

The market is experiencing significant growth due to the increased burden of cardiovascular diseases, which has boosted the demand for advanced targeted therapies. Innovation in gene therapy, regenerative medicine, and personalized approaches further support market expansion. Additionally, the growing adoption of minimally invasive procedures and AI-powered diagnostics is expected to fuel market growth in the coming years.

According to Precedence Research, drugs that specifically target disease-causing molecules or cells are becoming increasingly important in cardiovascular disease treatment. This demand further accelerates the drug development process by identifying potential drug candidates, predicting their efficacy, and optimizing clinical trial design. Patients and healthcare providers all over the world are increasingly opting for less invasive procedures due to benefits like faster recovery, reduced hospital stays, and lower risks. Thus, employing techniques of advanced catheter-based interventions results in faster recovery and reduced risks.

Artificial Intelligence is also helping in transforming cardiovascular treatments by helping in improving diagnostics, customizing therapies, and enhancing patient outcomes. AI algorithms can now analyze medical images, such as echocardiograms, CT scans, and ECGs, more accurately and efficiently than compared to traditional methods, enabling earlier diagnosis of conditions like coronary artery disease, heart failure, and valve disorders. 

Impact on the Cardiac Monitoring Market

The global cardiac monitoring market size is calculated at USD 10.06 billion in 2025 and is predicted to increase from USD 10.87 billion in 2026 to approximately USD 21.72 billion by 2035, expanding at a CAGR of 8.00% from 2026 to 2035.

According to Precedence Research, the market has been steadily growing in recent years as the incidence of cardiovascular diseases has increased, the elderly population has grown, and medical technology has advanced. The emerging economies all over the world are expected to provide a wide range of growth opportunities for market participants, owing to their large and growing populations, as well as an increasing number of hospitals and clinics in these countries.

The cardiac monitoring market is experiencing robust growth, driven by rising rates of cardiovascular disease (CVDs), an aging population, and technological shifts towards non-invasive, AI-powered remote monitoring (RPM) solutions. Key drivers for this growth include technological advancements like wireless connectivity, wearable monitors, and AI-based tools that improve diagnostic accuracy and accessibility. The market startup ecosystem is a vibrant, innovation-driven space characterized by the rapid development and adoption of wearable, AI-enabled, and remote patient monitoring (RPM) solutions.

Expert Opinion

Gaurav Agarwal, Managing Director of Innvolution Healthcare, said,

“Indonesia is an important market for Innvolution as we continue to strengthen our international presence. We have already established a strong foundation in the country through our cardiovascular consumables business, and we now see a significant opportunity to bring our cath lab solutions to the Indonesian market.”

“We have appointed Intralink to support us in identifying the right partners and navigating the local market with greater depth and focus. Its understanding of the Indonesian healthcare ecosystem, local market dynamics and ability to build the right strategic connections will be valuable as we establish our cath lab business in the country.”